Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies
Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies
复制标题
DOI：
10.1007/s10549-008-0143-x
复制
发表时间：
2009-06-01
影响因子：
3.8
通讯作者：
Kasimir-Bauer, Sabine
中科院分区：
文献类型：
--
作者：
Tewes, Mitra;Aktas, Bahriye;Kasimir-Bauer, Sabine
目的分析42例转移性乳腺癌患者血液中的循环肿瘤细胞（CTC），并确定该方法预测治疗反应的能力。方法采用AdnaTest BreastCancer检测治疗前和治疗中外周血CTC中EpCAM、MUC 1和HER 2的转录水平。RT-PCR检测雌激素（ER）和孕激素（PR）受体表达。结果CTC的总检出率为52%，其中EpCAM为86%，MUC 1为86%，HER 2为32%，ER为35%，PR为12%。在45%（ER）、78%（PR）和60%（HER-2）的类固醇受体阳性肿瘤患者中，CTC为ER、PR和HER-2阴性。29%的HER 2阴性肿瘤患者具有HER 2阳性CTC。该测试在78%的病例中预测了治疗反应。CTC的持续性与较短的总生存期显著相关（P = 0.005）。结论CTC的分子谱分析可为复发风险评估和治疗方案的预测提供上级预后信息。
Purpose We analyzed circulating tumor cells (CTC) in blood of metastatic breast cancer patients (n = 42) and determined the ability of this method to predict therapy response. Methods CTC from blood were analyzed before and during therapy for EpCAM, MUC1 and HER2 transcripts with the AdnaTest BreastCancer. The estrogen (ER) and progesterone (PR) receptor expression was assessed by RT-PCR. Results The overall detection rate for CTC was 52% (thereof 86% EpCAM; 86% MUC1; 32% HER2; 35% ER; 12% PR). CTC were ER, PR and HER2 negative in 45% (ER), 78% (PR) and 60% (HER-2) of patients with steroid receptor-positive tumors. 29% of patients with HER2-negative tumors had HER2-positive CTC. The test predicted therapy response in 78% of all cases. Persistence of CTC significantly correlated with shorter overall survival (P = 0.005). Conclusions Molecular profiling of CTC may offer superior prognostic information with regard to risk assessment for recurrence and predictive judgement of therapeutical regimens.